Skip to main content

Neuronet Meeting Newsroom

Conference Coverage
02/03/2025
Hannah Musick
Gain insights on navigating the future of neurological therapies from industry experts at the 2025 NeuroNet Pro Annual Summit.
Gain insights on navigating the future of neurological therapies from industry experts at the 2025 NeuroNet Pro Annual Summit.
Gain insights on navigating the...
02/03/2025
First Report Managed Care
Conference Coverage
01/31/2025
Hannah Musick
Panelists at the 2025 NeuroNet Pro Annual Summit discussed chronic care management, teleconsultations, and operational efficiency tools to support overwhelmed private practice neurologists.
Panelists at the 2025 NeuroNet Pro Annual Summit discussed chronic care management, teleconsultations, and operational efficiency tools to support overwhelmed private practice neurologists.
Panelists at the 2025 NeuroNet...
01/31/2025
First Report Managed Care
Conference Coverage
01/31/2025
Hannah Musick
A presentation at 2025 NeuroNet Pro Annual Summit outlines the current challenges and potential benefits of integrating imaging in-house for neurologists.
A presentation at 2025 NeuroNet Pro Annual Summit outlines the current challenges and potential benefits of integrating imaging in-house for neurologists.
A presentation at 2025 NeuroNet...
01/31/2025
First Report Managed Care
Conference Coverage
01/31/2025
Hannah Musick
Learn how the future of neurological care, marked by increasing patient demand, physician burnout, and shifts in treatment approaches, presents challenges and opportunities for neurologists to improve patient outcomes and create a more...
Learn how the future of neurological care, marked by increasing patient demand, physician burnout, and shifts in treatment approaches, presents challenges and opportunities for neurologists to improve patient outcomes and create a more...
Learn how the future of...
01/31/2025
First Report Managed Care

Conference Coverage
02/03/2025
Hannah Musick
Gain insights on navigating the future of neurological therapies from industry experts at the 2025 NeuroNet Pro Annual Summit.
Gain insights on navigating the future of neurological therapies from industry experts at the 2025 NeuroNet Pro Annual Summit.
Gain insights on navigating the...
02/03/2025
First Report Managed Care
Conference Coverage
01/31/2025
Hannah Musick
Panelists at the 2025 NeuroNet Pro Annual Summit discussed chronic care management, teleconsultations, and operational efficiency tools to support overwhelmed private practice neurologists.
Panelists at the 2025 NeuroNet Pro Annual Summit discussed chronic care management, teleconsultations, and operational efficiency tools to support overwhelmed private practice neurologists.
Panelists at the 2025 NeuroNet...
01/31/2025
First Report Managed Care
Conference Coverage
01/31/2025
Hannah Musick
A presentation at 2025 NeuroNet Pro Annual Summit outlines the current challenges and potential benefits of integrating imaging in-house for neurologists.
A presentation at 2025 NeuroNet Pro Annual Summit outlines the current challenges and potential benefits of integrating imaging in-house for neurologists.
A presentation at 2025 NeuroNet...
01/31/2025
First Report Managed Care
Conference Coverage
01/31/2025
Hannah Musick
Learn how the future of neurological care, marked by increasing patient demand, physician burnout, and shifts in treatment approaches, presents challenges and opportunities for neurologists to improve patient outcomes and create a more...
Learn how the future of neurological care, marked by increasing patient demand, physician burnout, and shifts in treatment approaches, presents challenges and opportunities for neurologists to improve patient outcomes and create a more...
Learn how the future of...
01/31/2025
First Report Managed Care
Conference Coverage
03/11/2026
Hannah Musick
As the Inflation Reduction Act (IRA) fundamentally restructures Medicare Part D financing, payers and manufacturers are recalibrating bid strategies, contracting models, and formulary decision-making ahead of 2026 implementation milestones.
As the Inflation Reduction Act (IRA) fundamentally restructures Medicare Part D financing, payers and manufacturers are recalibrating bid strategies, contracting models, and formulary decision-making ahead of 2026 implementation milestones.
As the Inflation Reduction Act...
03/11/2026
First Report Managed Care
Conference Coverage
03/10/2026
Hannah Musick
As oncology, rare disease, and gene therapy pipelines expand, managed care leaders are recalibrating specialty drug strategies to manage escalating costs while preserving patient access and clinical innovation.
As oncology, rare disease, and gene therapy pipelines expand, managed care leaders are recalibrating specialty drug strategies to manage escalating costs while preserving patient access and clinical innovation.
As oncology, rare disease, and...
03/10/2026
First Report Managed Care
Conference Coverage
03/09/2026
Hannah Musick
As states expand Prescription Drug Affordability Review Board (PDAB) authority and copay accumulator bans gain traction, managed care stakeholders are reassessing benefit design, reimbursement strategy, and contracting models in response to a...
As states expand Prescription Drug Affordability Review Board (PDAB) authority and copay accumulator bans gain traction, managed care stakeholders are reassessing benefit design, reimbursement strategy, and contracting models in response to a...
As states expand Prescription...
03/09/2026
First Report Managed Care
Conference Coverage
03/09/2026
Hannah Musick
Growing reliance on advanced analytics and real-world evidence is redefining reimbursement evaluation, prior authorization efficiency, and value-based contracting—signaling a shift toward more data-driven pharmacy benefit management.
Growing reliance on advanced analytics and real-world evidence is redefining reimbursement evaluation, prior authorization efficiency, and value-based contracting—signaling a shift toward more data-driven pharmacy benefit management.
Growing reliance on advanced...
03/09/2026
First Report Managed Care
Conference Coverage
11/06/2025
Grace Taylor, MS, MA
A study presented at ObesityWeek 2025 shows that adding structured exercise to calorie-restricted weight loss plans significantly increases daily, non-exercise physical activity in older adults with obesity.
A study presented at ObesityWeek 2025 shows that adding structured exercise to calorie-restricted weight loss plans significantly increases daily, non-exercise physical activity in older adults with obesity.
A study presented at ObesityWeek...
11/06/2025
First Report Managed Care
Conference Coverage
11/06/2025
Hannah Musick
A novel artificial intelligence (AI)-driven meta-analysis of obesity drug trials presented at ObesityWeek 2025 highlighted that GLP-1 receptor agonists and emerging multi-receptor therapies offer the greatest weight loss efficacy to date,...
A novel artificial intelligence (AI)-driven meta-analysis of obesity drug trials presented at ObesityWeek 2025 highlighted that GLP-1 receptor agonists and emerging multi-receptor therapies offer the greatest weight loss efficacy to date,...
A novel artificial intelligence...
11/06/2025
First Report Managed Care
Conference Coverage
11/05/2025
Hannah Musick
A quality improvement initiative demonstrated that partnering with an integrated specialty pharmacy significantly increased GLP-1 RA prescription fulfillment and patient enrollment in a pediatric obesity clinic, streamlining access and...
A quality improvement initiative demonstrated that partnering with an integrated specialty pharmacy significantly increased GLP-1 RA prescription fulfillment and patient enrollment in a pediatric obesity clinic, streamlining access and...
A quality improvement initiative...
11/05/2025
First Report Managed Care
Conference Coverage
11/05/2025
Hannah Musick
Oral bofanglutide demonstrated favorable safety, dose-dependent exposure, and meaningful weight reduction over 14 days, supporting its potential as a once-daily GLP-1 receptor agonist therapy for type 2 diabetes and obesity.
Oral bofanglutide demonstrated favorable safety, dose-dependent exposure, and meaningful weight reduction over 14 days, supporting its potential as a once-daily GLP-1 receptor agonist therapy for type 2 diabetes and obesity.
Oral bofanglutide demonstrated...
11/05/2025
First Report Managed Care
News
11/04/2025
Grace Taylor, MS, MA
A study presented at ObesityWeek by the Veterans Health Administration found that patients with type 2 diabetes taking GLP-1 receptor agonists showed significantly lower rates of unhealthy alcohol use, suggesting potential behavioral benefits...
A study presented at ObesityWeek by the Veterans Health Administration found that patients with type 2 diabetes taking GLP-1 receptor agonists showed significantly lower rates of unhealthy alcohol use, suggesting potential behavioral benefits...
A study presented at ObesityWeek...
11/04/2025
First Report Managed Care
Conference Coverage
11/04/2025
Hannah Musick
In a national cohort study presented at ObesityWeek 2025, GLP-1 receptor agonist use in dialysis patients with type 2 diabetes was associated with lower mortality, greater weight loss, and increased likelihood of transplant waitlisting,...
In a national cohort study presented at ObesityWeek 2025, GLP-1 receptor agonist use in dialysis patients with type 2 diabetes was associated with lower mortality, greater weight loss, and increased likelihood of transplant waitlisting,...
In a national cohort study...
11/04/2025
First Report Managed Care